دوره 12، شماره 10 - ( 8-1393 )                   جلد 12 شماره 10 صفحات 0-667 | برگشت به فهرست نسخه ها

XML English Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Davar R, Tabibnejad N, Kalantar S M, Sheikhha M H. The luteinizing hormone beta-subunit exon 3 (Gly102Ser) gene mutation and ovarian responses to controlled ovarian hyperstimulation. IJRM 2014; 12 (10) :667-0
URL: http://ijrm.ir/article-1-482-fa.html
داور رباب، طبیب نژاد نسیم، کلانتر سیدمهدی، شیخها محمدحسن. جهش اگزون 3 (Gly102Ser) زیر واحد بتاژن LH و پاسخ تخمدان به تحریک کنترل شده تخمدان . International Journal of Reproductive BioMedicine. 1393; 12 (10) :667-0

URL: http://ijrm.ir/article-1-482-fa.html


1- مرکز تحقیقاتی و درمانی ناباروری، دانشگاه علوم پزشکی شهیدصدوقی، یزد، ایران
2- مرکز تحقیقاتی و درمانی ناباروری، دانشگاه علوم پزشکی شهیدصدوقی، یزد، ایران ، sheikhha@yahoo.com
چکیده:   (2727 مشاهده)
مقدمه: علیرغم پیشرفت زیاد در روش­های IVF، یکی از مهم­ترین مشکلات متغیر بودن پاسخ به تحریک کنترل شده تخمدان (COH) می­باشد. مطالعات اخیر اثرات تفاوت­های ژنتیکی فردی را در نتایج COH نشان می­دهد.
هدف: هدف ار انجام مطالعه بررسی ارتباط بین پلی­مورفیسم LHβ G1502A در اگزون 3 ژن LH و پاسخ تخمدان به COH بود.
مواد و روش­ها: در کل 220 زن تحت درمان با پروتکل بلند تحریک تخمدان مورد مطالعه قرار گرفتند. سه ژنوتیپ GG، GA و AA بوسیله PCR-RFLP بررسی شد.
نتایج: در کل 34 بیمار (17%) دارای پاسخ ضعیف، 154 بیمار (77%) پاسخ نرمال و 12 نفر (6%) دارای پاسخ زیاد بودند. شایعترین ژنوتیپ (GA (55/5% بود در حالیکه (44/5%) بیماران ژنوتیپ GG بودند و هیچ بیماری ژنوتیپ AA نداشت. در کل 54/5% افراد با پاسخ نرمال و 61/8% افراد با پاسخ ضعیف و 50% افراد با پاسخ زیاد ژنوتیپ GA را نشان دادند.
نتیجه­گیری: نتایج ما ارتباطی را بین پلی­مورفیسم مورد بررسی و پاسخ تخمدان نشان ندادند. بنابراین هنوز بسیار مشکل است که این ژنوتیپ را در بیماران جهت پیش بینی پاسخ به درمان تحریک تخمدان استفاده نمود. 
نوع مطالعه: Original Article |

فهرست منابع
1. Society for Assisted Reproductive Technology; American Society for Reproductive Medicine. Assisted reproductive technology in the United States: 2001 results generated from the American Society for Reproductive Medicine/ Society for Assisted Reproductive Technology registry. Fertil Steril 2007; 87: 1253-1266. [DOI:10.1016/j.fertnstert.2006.11.056]
2. Verberg MF, Eijkemans MJ, Macklon NS, Heijnen EM, Baart EB, Hohmann FP, et al. The clinical significance of the retrieval of a low number of oocytes following mild ovarian stimulation for IVF: a meta-analysis. Hum Reprod Update 2009; 15: 5-12. [DOI:10.1093/humupd/dmn053]
3. Yong PY, Brett S, Baird DT, Thong KJ. A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone (Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment. Fertil Steril 2003; 79: 308-315. [DOI:10.1016/S0015-0282(02)04583-1]
4. Out HJ, Rutherford A, Fleming R, Tay CC, Trew G, Ledger W, et al. A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction. Hum Reprod 2004; 19: 90-95. [DOI:10.1093/humrep/deh044]
5. Themmen AP. An update of the pathophysiology of human gonadotrophin subunit and receptor gene mutations and polymorphisms. Reproduction 2005; 130: 263-274. [DOI:10.1530/rep.1.00663]
6. Perez Mayorga M, Gromoll J, Behre HM, Gassner C, Nieschlag E, Simoni M. Ovarian response to follicle-stimulating hormone (FSH) stimulation depends on the FSH receptor genotype. J Clin Endocrinol Metab 2000; 85: 3365-3369.
7. Jun JK, Yoon JS, Ku S, Choi YM, Hwang KR, Park SY, et al. Follicle stimulating hormone receptor gene polymorphism and ovarian responses to controlled ovarian hyperstimulation for IVF-ET. J Hum Genet 2006; 51: 665-670. [DOI:10.1007/s10038-006-0005-5]
8. Alviggi C, Clarizia R, Pettersson K, Mollo A, Humaidan P, Strina I, et al. Suboptimal response to GnRHa long protocol is associated with a common LH polymorphism. Reprod Biomed Online 2009; 18: 9-14. [DOI:10.1016/S1472-6483(10)60418-X]
9. Huhtaniemi I, Alevizaki M. Gonadotrophin resistance. Best Pract Res Clin Endocrinol Metab 2006; 20: 561-576. [DOI:10.1016/j.beem.2006.09.003]
10. Huhtaniemi IT, Themmen AP. Mutations in human gonadotropin and gonadotropin-receptor genes. Endocrine 2005; 26: 207-217. [DOI:10.1385/ENDO:26:3:207]
11. Loutradis D, Patsoula E, Minas V, Koussidis GA, Antsaklis A, Michalas S, et al. FSH receptor gene polymorphisms have a role for different ovarian response to stimulation in patients entering IVF/ICSI-ET programs. J Assist Reprod Genet 2006; 23: 177-184. [DOI:10.1007/s10815-005-9015-z]
12. Achrekar SK, Modi DN, Desai SK, Mangoli VS, Mangoli RV, Mahale SD. Poor ovarian response to gonadotrophin stimulation is associated with FSH receptor polymorphism. Reprod Biomed Online 2009; 18: 509-515. [DOI:10.1016/S1472-6483(10)60127-7]
13. Sheikhha MH, Eftekhar M, Kalantar SM. Investigating the association between polymorphism of follicle-stimulating hormone receptor gene and ovarian response in controlled ovarian hyperstimulation. J Hum Reprod Sci 2011; 4: 86-90. [DOI:10.4103/0974-1208.86089]
14. Piersma D, Verhoef-Post M, Look MP, Uitterlinden AG, Pols HAP, Berns EMJJ, et al. Polymorphic variations in exon 10 of the luteinizing hormone receptor: Functional consequences and associations with breast cancer. Mol Cell Endocrinol 2007; 276: 63-70. [DOI:10.1016/j.mce.2007.06.007]
15. Simoni M, Tuttelmann F, Michel C, Bockenfeld Y, Nieschlag E, Gromoll J. Polymorphisms of the luteinizing hormone/chorionic gonadotropin receptor gene: association with maldescended testes and male infertility. Pharmacogenet Genomics 2008; 18: 193-200. [DOI:10.1097/FPC.0b013e3282f4e98c]
16. Liao WX, Roy AC, Chan C, Arulkumaran S, Ratnam SS. A new molecular variant of luteinizing hormone associated with female infertility. Fertil Steril 1998; 69: 102-106. [DOI:10.1016/S0015-0282(97)00445-7]
17. Twigt JM, Hammiche F, Sinclair KD, Beckers NG, Visser JA, Lindemans J, et al. Preconception folic Acid use modulates estradiol and follicular responses to ovarian stimulation. J Clin Endocrinol Metab 2011; 96: E322-E329. [DOI:10.1210/jc.2010-1282]
18. Kim NK, Nam YS, Ko JJ, Chung HM, Chung KW, Cha KY: The luteinizing hormone b-subunit exon 3 (Gly102Ser) gene mutation is rare in Korean women with endometriosis and polycystic ovary syndrome. Fertil Steril 2001; 75: 1238-1239. [DOI:10.1016/S0015-0282(01)01806-4]
19. Van Voorhis BJ. Outcomes from assisted reproductive technology. Obstet Gynecol 2006; 107: 183-200. [DOI:10.1097/01.AOG.0000194207.06554.5b]
20. Fauser BC, Diedrich K, Devroey P. Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation. Hum Reprod Update 2008; 14: 1-14. [DOI:10.1093/humupd/dmm034]
21. Themmen APN, Huhtaniemi IT. Mutations of gonadotropins and gonadotropin receptors: elucidating the physiology and pathophysiology of pituitary-gonadal function. Endocr Rev 2000; 21: 551-583. [DOI:10.1210/edrv.21.5.0409]
22. Richter-Unruh A, Martens JWM, Verhoef-Post M, Wessels K, Kors WA, Sinnecker GHG, et al. Leydig cell hypoplasia: cases with new mutations, new polymorphism and cases without mutations in the luteinizing hormone receptor gene. Clin Endocrinol (Oxf) 2002; 56: 103-112. [DOI:10.1046/j.0300-0664.2001.01437.x]
23. Altmäe S, Hovatta O, Stavreus-Evers A, Salumets A. Genetic predictors of controlled ovarian hyperstimulation: where do we stand today? Hum Reprod Update 2011; 17: 813-828. [DOI:10.1093/humupd/dmr034]
24. Christofolini DM, Vilarino FL, Mafra FA, André GM, Bianco B, Barbosa CP. Combination of polymorphisms in luteinizing hormone β, estrogen receptor β and progesterone receptor and susceptibility to infertility and endometriosis. Eur J Obstet Gynecol Reprod Biol 2011; 158: 260-264. [DOI:10.1016/j.ejogrb.2011.06.028]
25. Hashad D, Mohamed N, Hashad MM. Luteinising hormone β-subunit gene Gly102Ser variant and oxidative stress biomarkers in Egyptian infertile males. Andrologia 2012; 44 (Suppl.): 484-489. [DOI:10.1111/j.1439-0272.2011.01212.x]
26. Kerkelä E, Skottman H, Friden B, Bjuresten K, Kere J, Hovatta O. Exclusion of coding-region mutations in luteinizing hormone and follicle-stimulating hormone receptor genes as the cause of ovarian hyperstimulation syndrome. Fertil Steril 2007; 87: 603-606. [DOI:10.1016/j.fertnstert.2006.06.060]
27. Maman E, Yung Y, Kedem A, Yerushalmi GM, Konopnicki S, Cohen B, et al. High expression of luteinizing hormone receptors messenger RNA by human cumulus granulosa cells is in correlation with decreased fertilization. Fertil Steril 2012; 97: 592-598. [DOI:10.1016/j.fertnstert.2011.12.027]
28. Bentov Y, Kenigsberg S, Casper RF. A novel luteinizing hormone/chorionic gonadotropin receptor mutation associated with amenorrhea, low oocyte yield, and recurrent pregnancy loss. Fertil Steril 2012; 97: 1165-1168. [DOI:10.1016/j.fertnstert.2012.02.002]
29. Papamentzelopoulou M, Mavrogianni D, Partsinevelos GA, Marinopoulos S, Dinopoulou V, Theofanakis C, et al. LH receptor gene expression in cumulus cells in women entering an ART program. J Assist Reprod Genet 2012; 29: 409-416. [DOI:10.1007/s10815-012-9729-7]
30. Mafra FA, Bianco B, Christofolini DM, Souza AM, Zulli K, Barbosa CP. Luteinizing hormone beta-subunit gene (LHbeta) polymorphism in infertility and endometriosis-associated infertility. Eur J Obstet Gynecol Reprod Biol 2010; 151: 66-69. [DOI:10.1016/j.ejogrb.2010.03.022]
31. Ramanujam LN, Liao WX, Roy AC, Loganath A, Goh HH, Ng SC: Association of molecular variants of luteinizing hormone with menstrual disorders. Clin Endocrinol (Oxf) 1999, 51: 243-246. [DOI:10.1046/j.1365-2265.1999.00791.x]
32. Liu N, Ma Y, Wang S, Zhang X, Zhang Q, Zhang X, et al. Association of the genetic variants of luteinizing hormone, luteinizing hormone receptor and polycystic ovary syndrome. Reprod Biol Endocrinol 2012, 10: 36. [DOI:10.1186/1477-7827-10-36]

ارسال پیام به نویسنده مسئول


بازنشر اطلاعات
Creative Commons License این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است.

کلیه حقوق این وب سایت متعلق به International Journal of Reproductive BioMedicine می باشد.

طراحی و برنامه نویسی : یکتاوب افزار شرق

© 2024 CC BY-NC 4.0 | International Journal of Reproductive BioMedicine

Designed & Developed by : Yektaweb